Netrin-1 & Hepatocellular Carcinoma HCC

NCT ID: NCT04766736

Last Updated: 2021-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

320 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HCC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)

The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)

Quantification of netrin-1 signals by antibody-based approaches

Intervention Type PROCEDURE

Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.

Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)

The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)

Quantification of netrin-1 signals by antibody-based approaches

Intervention Type PROCEDURE

Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quantification of netrin-1 signals by antibody-based approaches

Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* any patient suffering from HCC
* age \>18
* informed consent provided

Exclusion Criteria

\- absence of informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hepatogastroenterology service of the Croix-Rousse Hospital

Lyon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fabien ZOULIM, Pr

Role: CONTACT

4 26 10 93 55 ext. +33

Romain PARENT

Role: CONTACT

4 72 68 19 70 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fabien ZOULIM, Pr

Role: primary

4 26 10 93 55 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL19_0258

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Detect and Expunge Concealed Tumors of the Liver
NCT06141564 ACTIVE_NOT_RECRUITING
Development of a Neuronal Microscope
NCT06311396 ACTIVE_NOT_RECRUITING NA